Lasofoxifene and cardiovascular events in postmenopausal women with osteoporosis: Five-year results from the Postmenopausal Evaluation and Risk Reduction with Lasofoxifene (PEARL) trial.

Publication Type:

Journal Article

Authors:

Ensrud, Kristine; LaCroix, Andrea Z; Thompson, John R; Thompson, David D; Eastell, Richard; Reid, David M; Vukicevic, Slobodan; Cauley, Jane; Barrett-Connor, Elizabeth; Armstrong, Roisin; Welty, Francine; Cummings, Steven

Source:

Circulation, Volume 122, Issue 17, p.1716-24 (2010)

Keywords:

2010, Aged, Aged, 80 and over, Breast Neoplasms, Center-Authored Paper, Coronary Disease, Dose-Response Relationship, Drug, Double-Blind Method, Endpoint Determination, Female, Follow-Up Studies, Fractures, Bone, Humans, Incidence, Longitudinal Studies, Middle Aged, Osteoporosis, Postmenopausal, Public Health Sciences Division, Pyrrolidines, Receptors, Estrogen, Risk Factors, Stroke, Tetrahydronaphthalenes, Treatment Outcome

Abstract:

In the Postmenopausal Evaluation and Risk Reduction With Lasofoxifene (PEARL) trial, women assigned to lasofoxifene 0.5 mg/d had a lower risk of major coronary heart disease (CHD) events and stroke, whereas women assigned to lasofoxifene 0.25 mg/d had a lower risk of stroke. Both doses of lasofoxifene increased the risk of venous thromboembolic events. In this report, we provide comprehensive cardiovascular end-point data, including component events comprising the composite end point of major CHD events, and evaluate whether the effect of lasofoxifene 0.5 mg/d is consistent across different categories of CHD risk.